Clinical Trial Update: Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B

View source ↗

Summary

This trial update notes the completion of a study evaluating pegylated interferon alfa-2a (Pegasys) for HBeAg-positive chronic hepatitis B.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: China Medical University Hospital | Conditions: Hepatitis B, Chronic | Status: COMPLETED